About Us
Innovative Drugs
Innovation Platform
News
Join Us
Contact Us
Keyword:
Latest News
Jiangsu Vcare Announces First Patient Enrollment in Phase Ⅱ Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo
Jiangsu Vcare Completes Phase III Enrollment of VC005, a Next-Generation High-Selective JAK1 Inhibitor for Moderate-to-Severe Atopic Dermatitis
Jiangsu Vcare Launches Phase III Clinical Trial of VC005, a Highly Selective JAK1 Inhibitor, for Ankylosing Spondylitis
Jiangsu Vcare Initiates Phase II Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo
Vcare Enters into Exclusive Partnership with Huadong Medicine to Commercialize its second-generation JAK1 inhibitor, VC005 tablets, in China
Jiangsu Vcare Completes Full Patient Enrollment for Phase II Clinical Trial of VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis